Patient-specific tumor-associated antigens presented on MHC class II (TSA-MHC II)

Patient-specific tumor-associated antigens (TSAs) presented on MHC class II molecules are unique peptides derived from non-synonymous somatic mutations found exclusively within an individual's tumor cells. These neoantigens are processed by professional antigen-presenting cells and displayed via Major Histocompatibility Complex (MHC) class II molecules to CD4+ T helper cells, which are essential for orchestrating a comprehensive anti-tumor immune response (Sahin et al., 2017, Nature). While historical focus was often on MHC class I-restricted antigens for CD8+ cytotoxic responses, recent research highlights that MHC class II-restricted neoantigens are frequently more immunogenic and critical for sustained therapeutic efficacy and epitope spreading (Alspach et al., 2019, Nature). In clinical applications, these antigens are identified through whole-exome sequencing and bioinformatic algorithms to design personalized vaccines, such as mRNA or peptide-based platforms (Ott et al., 2017, Nature). These vaccines aim to prime the patient's immune system to recognize the 'non-self' mutational landscape of the cancer, providing a highly specific therapeutic approach with minimal off-target effects on healthy tissue (Kreiter et al., 2015, Nature). This target class represents a cornerstone of next-generation precision oncology and cancer immunotherapy.

Other names

MHC class II-restricted neoantigensTumor-specific neoantigensPersonalized cancer antigensMHC-II neoepitopesSomatic mutation-derived antigens

Induction of personalized, antigen-specific CD4+ T-cell responses to recognize and coordinate the destruction of tumor cells expressing specific mutated peptides.